ARP Americas LP increased its stake in Horizon Pharma PLC (NASDAQ:HZNP) by 20.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 14,100 shares of the biopharmaceutical company’s stock after purchasing an additional 2,400 shares during the period. ARP Americas LP’s holdings in Horizon Pharma were worth $276,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in HZNP. California State Teachers Retirement System raised its holdings in Horizon Pharma by 3.9% in the 4th quarter. California State Teachers Retirement System now owns 262,873 shares of the biopharmaceutical company’s stock valued at $5,137,000 after acquiring an additional 9,889 shares during the period. Stifel Financial Corp raised its holdings in Horizon Pharma by 4.4% in the 4th quarter. Stifel Financial Corp now owns 160,645 shares of the biopharmaceutical company’s stock valued at $3,155,000 after acquiring an additional 6,738 shares during the period. Granite Investment Partners LLC bought a new position in Horizon Pharma in the 4th quarter valued at about $915,000. Gideon Capital Advisors Inc. bought a new position in Horizon Pharma in the 4th quarter valued at about $249,000. Finally, United Services Automobile Association raised its holdings in Horizon Pharma by 10.6% in the 4th quarter. United Services Automobile Association now owns 28,282 shares of the biopharmaceutical company’s stock valued at $553,000 after acquiring an additional 2,721 shares during the period. 88.83% of the stock is owned by hedge funds and other institutional investors.

Shares of HZNP opened at $27.31 on Friday. Horizon Pharma PLC has a 12 month low of $12.55 and a 12 month high of $29.44. The company has a market cap of $4.61 billion, a PE ratio of 14.92, a price-to-earnings-growth ratio of 1.49 and a beta of 1.16. The company has a current ratio of 2.03, a quick ratio of 1.97 and a debt-to-equity ratio of 1.80.

Horizon Pharma (NASDAQ:HZNP) last announced its earnings results on Wednesday, February 27th. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.54 by $0.13. The company had revenue of $355.50 million for the quarter, compared to analysts’ expectations of $334.22 million. Horizon Pharma had a negative net margin of 6.34% and a positive return on equity of 34.09%. The business’s revenue for the quarter was up 29.6% on a year-over-year basis. During the same period last year, the firm earned $0.29 earnings per share. As a group, equities analysts predict that Horizon Pharma PLC will post 1.74 EPS for the current year.

Several research analysts have weighed in on HZNP shares. BidaskClub cut shares of Horizon Pharma from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 29th. Mizuho reissued a “hold” rating and issued a $21.00 price target on shares of Horizon Pharma in a report on Thursday, February 7th. Cowen set a $33.00 price target on shares of Horizon Pharma and gave the company a “buy” rating in a report on Thursday, February 28th. Piper Jaffray Companies set a $26.00 price target on shares of Horizon Pharma and gave the company a “buy” rating in a report on Monday, January 14th. Finally, Morgan Stanley raised shares of Horizon Pharma from an “equal weight” rating to an “overweight” rating and set a $32.00 price target on the stock in a report on Friday, March 8th. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $28.09.

In related news, EVP Geoffrey M. Curtis sold 10,080 shares of the stock in a transaction that occurred on Monday, February 25th. The shares were sold at an average price of $21.21, for a total transaction of $213,796.80. Following the sale, the executive vice president now owns 35,367 shares in the company, valued at approximately $750,134.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Geoffrey M. Curtis sold 8,835 shares of the stock in a transaction that occurred on Tuesday, February 5th. The stock was sold at an average price of $23.15, for a total transaction of $204,530.25. Following the sale, the executive vice president now owns 32,202 shares in the company, valued at approximately $745,476.30. The disclosure for this sale can be found here. Company insiders own 3.90% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2019/03/15/horizon-pharma-plc-hznp-shares-bought-by-arp-americas-lp.html.

Horizon Pharma Profile

Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.

Further Reading: QQQ ETF

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.